How much cash does Dogwood Therapeutics generate?

Dogwood Therapeutics (DWTX) generated -$15.5M in operating cash flow over the trailing twelve months.

Where does Dogwood Therapeutics's cash flow data come from?

Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Dogwood Therapeutics DWTX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$28.32M-28.8%	-$34.26M-177%	-$38.2M-567%	-$24.74M-429%	-$21.98M-334%
Depreciation and amortization	——	——	——	$40.37K—	$26.15K—
Stock-based compensation	$720.59K+70.9%	$355.64K-25.3%	$291.58K-45.0%	$337.61K-42.2%	$421.53K-29.4%
Deferred income taxes	$31.75K-83.3%	$221.1K+44,055%	$188.75K—	$190.19K—	$190.04K—
Amortization of debt issuance costs	——	——	——	——	$96.2K—
Gain (loss) on sale of assets	——	-$2.73K—	——	——	——
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	$979.47K+260%	$608.29K+301%	-$629.27K-205%	-$535.38K-2,187%	-$612.48K-1,399%
Change in other assets	-$8.39K-102%	$208.69K-58.2%	$934.91K—	$334.98K—	$430.33K—
Non-cash operating lease expense	——	——	——	——	——
Loss on extinguishment of debt	——	——	——	——	——
Net cash from operating activities	-$15.52M-23.8%	-$15.62M-77.7%	-$18.11M-339%	-$15.75M-277%	-$12.54M-205%
Acquisitions, net of cash acquired	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Net cash from financing activities	——	——	——	——	——
Effect of exchange rate changes on cash	——	——	——	-$61.01K—	-$107.21K—
Net increase (decrease) in cash	-$4.32M-128%	-$8.33M-171%	$8.22M+399%	$10.52M+695%	$15.3M+586%
Amortization expense related to capitalized debt issuance costs	——	——	——	——	$96.2K—
Depreciation	——	——	——	$40.37K—	$26.15K—
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——	-$29.98K—
Accrued expenses and other liabilities	$979.47K+260%	$608.29K+301%	-$629.27K-209%	-$535.38K-604%	-$612.48K-1,397%
Increase (Decrease) in Prepaid Expense and Other Assets	-$8.39K-102%	$208.69K-58.2%	$934.91K—	$334.98K—	$430.33K—
Merger-related charges and other	——	——	——	——	——
Operating Lease Deferred Sublease Income	——	——	——	——	——
Operating lease right-of-use asset amortization	——	——	——	——	——
Payments Of Fractional Shares For Reverse Stock Split	——	——	——	——	——
Payments Of Stock Issuance Costs	$146.62K—	$53.81K—	——	——	——
Proceeds From Related Party Debt	——	——	——	——	$14.49M—
Proceeds From Warrant Exercises	——	——	——	——	——
Sale Of Stock Consideration Received On Transaction	——	——	——	——	——
Exchange Offer (Note 12)	——	$110.46M—	——	——	——
Debt Conversion Accrued Interest On Debt Amount	——	——	——	——	——
Debt Conversion Original Debt Amount1	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	-$61.01K—	-$107.21K—
Issuance Costs Included In Accounts Payable And Accrued Expenses	——	$106.27K—	——	——	——
Non Cash Preferred Stock Dividends	——	——	——	——	$1.64M—
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Preferred Shares Issued	——	——	——	——	——
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Common Shares Issued	——	——	——	——	——
Offering Costs Included In Accounts Payable And Accrued Expenses	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Dogwood Therapeutics generate?: Dogwood Therapeutics (DWTX) generated -$15.5M in operating cash flow over the trailing twelve months.
Where does Dogwood Therapeutics's cash flow data come from?: Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.